https://www.selleckchem.com/pr....oducts/nms-p937-nms1
The current study evaluates survival rates among Systemic Sclerosis-associated Pulmonary Arterial Hypertension (SSc-PAH) patients on intravenous (IV) prostanoids, and short-term impact of IV prostanoids on clinical and haemodynamic parameters. Baseline demographics, invasive and non-invasive data, ESC (European Society of Cardiology) score and REVEAL score of 81 SSc-PAH patients (median age 61 years, interquartile range 54-67 years, 84% females) were prospectively recorded, from November 2006 till November 2020, before initi
Beğen
Yorum Yap
Paylaş
